Understand the source comparison
Pinealon vs Other Research Peptides: TSA Treatment Comparison
Pinealon (Lys-Glu-Asp-Gly) Not scheduled. Legal research compound 2–8°C reconstituted, −20°C lyophilised Institutional letter + supplier invoice + MSDS Low if properly documented Passes screening quickly with correct paperwork and cold storage proof BPC-157 Id
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Pinealon (Lys-Glu-Asp-Gly)
- Not scheduled. Legal research compound
- 2–8°C reconstituted, −20°C lyophilised
- Institutional letter + supplier invoice + MSDS
- Low if properly documented
- Passes screening quickly with correct paperwork and cold storage proof
- BPC-157
- Identical treatment to Pinealon. Documentation determines outcome
- Thymosin Beta-4
- Not scheduled but FDA-regulated
- Institutional letter + supplier invoice + MSDS + research protocol summary
- Moderate. Longer secondary screening
- Agent scrutiny higher due to FDA guidance on clinical use restrictions
- Melanotan II
- Not scheduled but associated with cosmetic misuse
- High. Frequent secondary screening
- Often flagged for additional questioning due to recreational tanning associations
- Research-grade insulin (non-prescription)
- Not scheduled when labelled for research
- 2–8°C always
- Institutional letter + supplier invoice proving research grade, not pharmaceutical
- Moderate to high without clear labelling
- Agents assume pharmaceutical insulin unless documentation proves research application
- Semaglutide (research formulation)
- Not scheduled but FDA-approved drug exists
- 2–8°C reconstituted
- Institutional letter + supplier invoice + MSDS + declaration it's research-grade not pharmaceutical
- High. Extended secondary screening common
- Confusion with prescription Ozempic/Wegovy triggers additional verification steps